Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)



Status:Recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/13/2019
Start Date:December 18, 2015
End Date:August 28, 2023
Contact:Toll Free Number
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic)
solid tumors that have progressed on standard of care therapy will be treated with
pembrolizumab.


Inclusion Criteria:

- Histologically or cytologically-documented, advanced solid tumor of one of the
following types:

- Anal Squamous Cell Carcinoma

- Biliary Adenocarcinoma (gallbladder or biliary tree (intrahepatic or extrahepatic
cholangiocarcinoma) except Ampulla of Vater cancers)

- Neuroendocrine Tumors (well- and moderately-differentiated) of the lung,
appendix, small intestine, colon, rectum, or pancreas

- Endometrial Carcinoma (sarcomas and mesenchymal tumors are excluded)

- Cervical Squamous Cell Carcinoma

- Vulvar Squamous Cell Carcinoma

- Small Cell Lung Carcinoma

- Mesothelioma

- Thyroid Carcinoma

- Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)

- OR

- Any advanced solid tumor, with the exception of colorectal carcinoma (CRC), which
is Microsatellite Instability (MSI)-High (MSI-H)

- Progression of tumor or intolerance to therapies known to provide clinical benefit.
There is no limit to the number of prior treatment regimens

- Can supply tumor tissue for study analyses (dependent on tumor type)

- Radiologically-measurable disease

- Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
Performance Scale within 3 days prior to first dose of pembrolizumab

- Life expectancy of at least 3 months

- Adequate organ function

- Female participants of childbearing potential must be willing to use adequate
contraception for the course of the study through 120 days after the last dose of
study medication

- Male participants with partners of must childbearing potential must be willing to use
adequate contraception for the course of the study through 120 days after the last
dose of study medication

Exclusion Criteria:

- Currently participating and receiving study therapy or has participated in a study of
an investigational agent and received study therapy or used an investigational device
within 4 weeks of the first dose of study medication

- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form
of immunosuppressive therapy within 7 days prior to the first dose of study medication

- Active autoimmune disease that has required systemic treatment in the past 2 years

- Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not
recovered from an adverse event caused by mAbs administered more than 4 weeks earlier

- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2
weeks of study Day 1 or not recovered from adverse events caused by a previously
administered agent

- Known additional malignancy within 2 years prior to enrollment with the exception of
curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the
skin and/or curatively resected in situ cancers

- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

- Has known glioblastoma multiforme of the brainstem

- History of non-infectious pneumonitis that required steroids or current pneumonitis

- Active infection requiring systemic therapy

- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the study

- Pregnant, breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of study medication

- Previously participated in any other pembrolizumab (MK-3475) study, or received prior
therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1),
anti-PD-L2, or any other immunomodulating mAb or drug specifically targeting T-cell
co-stimulation or checkpoint pathways

- Known history of Human Immunodeficiency Virus (HIV)

- Known active Hepatitis B or C

- Received live vaccine within 30 days of planned start of study medication

- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients

- Known history of active tuberculosis (TB, Bacillus tuberculosis)
We found this trial at
14
sites
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
North Ryde, 2113
Phone: 61 2 8988 8428
?
mi
from
North Ryde,
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Rockville, MD
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials